SOLUTION PROVIDER Q&A Sponsored Content
Driving Growth and Expanding Downstream Service Opportunities with Virtual Genetic Services
Jill Davies MS CCGC, Chief Executive Officer
Genome Medical
What role does telehealth genetic services play in a health system setting? To many, genetics is simply a swab or blood draw to perform the test and sequencing. The first genome was sequenced in about 13 years. It now can be done in a mat- ter of minutes. There has been great progress in testing, but now you have terabytes of data that need to be ana- lyzed and put into clinical context for a specific individual. Genetic professionals solve that last mile of the equa-
tion to help the patients navigate their genetics journey. We analyze and interpret the genetic information and work with the patient and/or their care team to make it meaning- ful and actionable. Genetics can be applied to virtually all areas of medicine to support personalized patient care. Its value and utility has expanded over the years from pediat- rics and reproductive specialties to cardiology, neurology and oncology, which is the largest growth area of genetics in a clinical setting.
How can hospitals use telehealth to improve access to genetics care? Historically most genetic services were offered in-person at academic medical centers making access difficult. Telehealth genetic services (telegenetics) make it possible to deliver this care to patients regardless of location. This really opens access to anyone that needs it, without an often months-long wait time. Telegenetics helps expand access to genetics profes-
sionals and keep patients close to home, in their local health system. Telehealth services are an extension of the care patients are receiving from their local provider and helps the provider deliver high-quality care while unlocking growth as a result of the downstream services they can offer.
How can telehealth address workforce shortage issues? Are there learnings in genetics that could be applied to telehealth delivery more broadly? We hear a lot right now about workforce shortages. This is an issue that isn’t new to genetics. We’ve been working to solve for workforce shortages for several years. As the opportunities for more patients to access genetics have proliferated, we haven’t been able to match pace with the number of genetics professionals trained to support those patients and their care team. Beyond telehealth delivery, genetics services compa-
nies like Genome Medical have developed technology platforms and tools that help health systems increase efficiency and scale services without increasing their
staffing. Additionally, we have been advancing the development of the Genetic Counseling Assistant role that supports administrative components and enables genetic counselors to practice at the “top of their scope” to further scale delivery and efficiency. What we’ve learned in genet- ics can be used to continue to evolve models of care and innovate to address workforce shortages across other areas of healthcare delivery.
How are genetics technology solutions supporting health systems with downstream service opportunities? As hospitals deal with cost pressures, programs like genet- ics, provide opportunities to drive new revenue streams. For example in oncology, many individuals would benefit from having a genetic test for cancer, to identify or refine their risk. We’ve created a solution that takes the burden off of a health system and identifies those individuals, and brings them into the health system where they can receive services and care. For those at high-risk, there are follow-on services such as imaging or other services that drive revenue back into the hospital. Ultimately it comes down to improving patient care. If we can identify patients at high-risk, and get them early screening and detection, we can intervene before cancer develops.
How will the overall genetic services landscape evolve in the future? Twenty years ago I couldn’t have predicted where we are today. There has been exponential growth and new areas of practice for genetics. In the last couple of years, we’ve seen the impact of genetics in life sciences. For patients with rare diseases, we used to help them identify the disease and then support them in living with it. Today, in the pediatric space, we are seeing life changing innovations. Biopharma companies are developing new therapies that target and correct the genetic variants that cause rare diseases. I think we’ll see continued evolution from applying genetics simply for care management to also therapeutic innovations that stop or alter disease progression. As we continue to navigate the challenges in healthcare:
workforce challenges, financial constraints, new and dispa- rate solutions, I think partnership is the way forward. It’s the only way we are going to be able to provide the quality of care that patients need. We are excited to continue on that journey, supporting healthcare organizations to improve access to actionable genetic care that improves lives.
www.genomemedical.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36
